Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.56 USD | -9.18% | +16.72% | +16.72% |
05-02 | Earnings Flash (CDXS) CODEXIS Posts Q1 Revenue $17.1M, vs. Street Est of $13.3M | MT |
05-02 | Transcript : Codexis, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.72% | 277M | B- | ||
+22.81% | 47.9B | B- | ||
+46.56% | 41.42B | A | ||
-1.88% | 40.7B | B | ||
-6.20% | 28.92B | C | ||
+11.33% | 25.55B | B- | ||
-21.00% | 19.27B | B | ||
-1.43% | 12.15B | B+ | ||
+30.73% | 12.14B | C+ | ||
-0.48% | 11.99B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CDXS Stock
- Ratings Codexis, Inc.